Service:
OWL sells analytical services based on proprietary Metabolomic platform patented protocols and products:
OWLiver®, the only non-invasive and first CE-marked in-vitro blood-based diagnostic for NASH (non-alcoholic steatohepatitis or liver inflammation with fibrosis).
OWLiver Care® discriminates healthy from fatty liver; only for Pharma
companies use. Other products in the pipeline.
OWL offers spercialised metabolomic services to Pharma and Biotech companies in the areas of biomarker discovery, clinical studies, companion diagnostics and toxicology.
OWLiver®, the only non-invasive and first CE-marked in-vitro blood-based diagnostic for NASH (non-alcoholic steatohepatitis or liver inflammation with fibrosis).
OWLiver Care® discriminates healthy from fatty liver; only for Pharma
companies use. Other products in the pipeline.
OWL offers spercialised metabolomic services to Pharma and Biotech companies in the areas of biomarker discovery, clinical studies, companion diagnostics and toxicology.
Advantage:
OWLiver® is non-invasive, more affordable than the other reliable competing technologies (biopsy, MRI), it is scalable, uses standard lab platform, does not depend on human operator’s interpretation or expertise.
Market opportunity:
3,6 M liver biopsies are prescribed annually in the US and EU for NASH. With a cost of 180€, OWLiver® would represent a 650 M€ immediate opportunity.
Commercial Status
Intellectual Property
US, MX, CA granted, extending to WO
Tested in humans?
clinical validation done
FDA approval?
in process, expected for 2021
CE approval?
December 2017
US reimbursement?
Exp. December 2021
EU reimbursement?
Spain; others in process
Currently selling?
Spain and Mexico
USA exp. 2Q-2019 through a CLIA lab
USA exp. 2Q-2019 through a CLIA lab
links of interest
